Juan José Segura-Sampedro

Dr. Juan José Segura-Sampedro

Oncologic Surgery, Hospital Universitario La Paz, Madrid, Spain
+2
orcid
Oncologic Surgeon

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
ABAneel Bhangu
Aneel Bhangu
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
MAMaria Lorena Aguilera
Maria Lorena Aguilera
PAPhilip Alexander
Philip Alexander
SASara W Al-Saqqa
Sara W Al-Saqqa
RBRuth Blanco
Ruth Blanco
Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p<0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05-2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p<0·001). Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication. DFID-MRC-Wellcome Trust Joint Global Health Trial Development Grant, National Institute of Health Research Global Health Research Unit Grant.

1 August 2019 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
JRJavier Ripollés-Melchor
Javier Ripollés-Melchor
JRJose-M Ramirez
Jose-M Ramirez
RCRubén Casans-Francés
Rubén Casans-Francés
CACesar Aldecoa
Cesar Aldecoa
AAAne Abad-Motos
Ane Abad-Motos
Juan José Segura-SampedroJuan José Segura-Sampedro
Juan José Segura-Sampedro
An estimated 310 million patients undergo surgery worldwide each year.1 The International Surgical Outcomes Study reported that, globally, 26.8% of patients who underwent major surgery had postoperative complications, and 24.3% of those who underwent low abdominal surgery developed complications.2 These findings are similar to those of a previous study.3 Postoperative complications after major surgery have been shown to increase the length of stay (LOS), cost, and mortality.4-6 Moreover, the presence of postoperative complications after colorectal surgery was associated with decreased long-term survival, independent of patient, disease, and treatment factors.3

1 November 2021 in The Lancet Oncology
Verified
Journal Article
Open access
JGJames Glasbey
James Glasbey
AAAdesoji Ademuyiwa
Adesoji Ademuyiwa
AAAdewale Adisa
Adewale Adisa
EAEhab AlAmeer
Ehab AlAmeer
AAAlexis P Arnaud
Alexis P Arnaud
MAM Aldawbali
M Aldawbali
Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.

6 July 2021 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
PBPlacido Bruzzaniti
Placido Bruzzaniti
JVJ I Valenzuela
J I Valenzuela
LBL A Boccalatte
L A Boccalatte
NGN A Gemelli
N A Gemelli
DSD E Smith
D E Smith
HNHamza Al Naggar
Hamza Al Naggar
Since the beginning of the COVID-19 pandemic tens of millions of operations have been cancelled 1 as a result of excessive postoperative pulmonary complications (51.2 per cent) and mortality rates (23.8 per cent) in patients with perioperative SARS-CoV-2 infection 2. There is an urgent need to restart surgery safely in order to minimize the impact of untreated non-communicable disease.

Verified
Journal Article
Open access
PDF file
ACAlice Chaplin
Alice Chaplin
RRRamon Maria Rodriguez
Ramon Maria Rodriguez
Juan José Segura-SampedroJuan José Segura-Sampedro
Juan José Segura-Sampedro
AOAina Ochogavía-Seguí
Aina Ochogavía-Seguí
DRDora Romaguera
Dora Romaguera
Gwendolyn Barceló-CoblijnGwendolyn Barceló-Coblijn
Gwendolyn Barceló-Coblijn
Colorectal cancer (CRC) is a major health problem worldwide, with an estimated 1.9 million new cases and 915,880 deaths in 2020 alone. The etiology of CRC is complex and involves both genetic and lifestyle factors. Obesity is a major risk factor for CRC, and the mechanisms underlying this link are still unclear. However, the generalized inflammatory state of adipose tissue in obesity is thought to play a role in the association between CRC risk and development. Visceral adipose tissue (VAT) is a major source of proinflammatory cytokines and other factors that contribute to the characteristic systemic low-grade inflammation associated with obesity. VAT is also closely associated with the tumor microenvironment (TME), and recent evidence suggests that adipocytes within the TME undergo phenotypic changes that contribute to tumor progression. In this review, we aim to summarize the current evidence linking obesity and CRC, with a focus on the role of VAT in tumor etiology and progression.

1 January 2021 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Closed access
EFEster Ferrer-Inaebnit
Ester Ferrer-Inaebnit
FMFrancesc Xavier Molina-Romero
Francesc Xavier Molina-Romero
Juan José Segura-SampedroJuan José Segura-Sampedro
Juan José Segura-Sampedro
XGXavier González-Argenté
Xavier González-Argenté
JCJosé Miguel Morón Canis
José Miguel Morón Canis
Hydatidosis is a zoonosis caused by Echinococcus in the larval stage. Humans are accidental intermediary hosts where cystic lesions develop, primarily in the liver and lungs. It is usually asymptomatic, hence it is usually incidentally identified. Symptoms result from cyst expansion and/or host inflammatory reaction. Hepatomegaly is the most common sign. Hydatidosis induces no specific changes in lab tests, but immunodiagnostics are available that may complement its study, with antibody detection being the method of choice. While ultrasound is the main diagnostic technique, tomography offers more accurate information regarding characteristics and anatomical relations. A number of therapy options are presently available. Treatment with albendazole, whether combined or not with praziquantel, is useful for smaller, uncomplicated cysts (< 5 cm). Only 30 % of cysts disappear with medical treatment alone. Surgery is indicated for bigger liver cysts (> 10 cm), at risk for rupture and/or complicated; the laparoscopic approach is scarcely widespread. The radical technique (total cystopericystectomy) is preferable because o its lower risk for postoperative abdominal infection, biliary fistula, and overall morbidity. Conservative techniques are appropriate in endemic areas where surgery is performed by nonspecialist surgeons. PAIR (puncture-aspiration-injection-reaspiration) is an innovative technique representing an alternative to surgery. It is indicated for inoperable cases and/or patients who reject surgery, for recurrence after surgery, and for lack of response to medical treatment. Active surveillance without treatment may be indicated for quiescent or inactive, uncomplicated liver cysts.